文献速递类风湿关节炎脊柱关节炎其他结缔组织病

TNFi与SARS-CoV-2感染较好结局相关,而JAKi和利妥昔单抗与较差结局相关

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.
PubMed 文献 · RMD Open · 2021-01-01

基于德国COVID-19-RMD注册库2020年3月30日至2021年4月9日收集的2274例炎症性风湿与肌肉骨骼疾病(RMD)患者数据,分析不同RMD治疗与SARS-CoV-2感染结局的关联。多变量有序逻辑回归显示,与甲氨蝶呤(MTX)相比,TNF抑制剂(TNFi)与较好结局独立相关(OR 0.6,95%CI 0.4-0.9),而免疫抑制剂、JAK抑制剂(JAKi)和利妥昔单抗与较差结局独立相关。

要点

  • 与MTX相比,TNFi与SARS-CoV-2感染较好结局独立相关(OR 0.6,95%CI 0.4-0.9)。
  • 免疫抑制剂(OR 2.2)、JAKi(OR 1.8)和利妥昔单抗(OR 5.4)与较差结局独立相关。
  • 疾病活动和糖皮质激素与较差结局相关,即使无糖皮质激素高疾病活动患者结局仍较差。

核心结论

  • 在RMD患者中,TNFi与SARS-CoV-2感染较好结局相关,而免疫抑制剂、JAKi和利妥昔单抗与较差结局相关。
  • 疾病活动对COVID-19结局影响重要,高疾病活动患者即使无糖皮质激素结局仍较差。

研究设计与样本

  • 分析德国COVID-19-RMD注册库2020年3月30日至2021年4月9日收集的数据,共纳入2274例患者。
  • 采用多变量有序逻辑回归(比例优势模型)评估 demographic 和疾病特征与COVID-19结局的独立关联。
  • COVID-19严重程度有序结局定义:1=未住院,2=住院/未侵入性通气,3=侵入性通气/死亡。

主要发现

  • 83例(3.6%)患者死亡。
  • 年龄、男性、心血管疾病、高血压、慢性肺病和慢性肾病与SARS-CoV-2感染较差结局独立相关。
  • 与类风湿关节炎相比,银屑病关节炎患者结局更好。
  • 与MTX相比,TNFi与较好结局显著相关(OR 0.6,95%CI 0.4-0.9)。
  • 免疫抑制剂(OR 2.2,95%CI 1.3-3.9)、JAKi(OR 1.8,95%CI 1.1-2.7)和利妥昔单抗(OR 5.4,95%CI 3.3-8.8)与较差结局独立相关。

关键数值与推荐

  • 与MTX相比,TNFi的OR为0.6(95%CI 0.4-0.9)。
  • 免疫抑制剂的OR为2.2(95%CI 1.3-3.9)。
  • JAKi的OR为1.8(95%CI 1.1-2.7)。
  • 利妥昔单抗的OR为5.4(95%CI 3.3-8.8)。

临床怎么用

  • RMD患者感染SARS-CoV-2时,使用TNFi者结局可能较好,使用JAKi、利妥昔单抗或免疫抑制剂者需警惕较重病程。
  • 控制疾病活动可能有助于改善COVID-19结局,高疾病活动患者即使未用糖皮质激素风险仍较高。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Several risk factors for severe COVID-19 specific for patients with inflammatory rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence regarding the influence of different RMD treatments on outcomes of SARS-CoV-2 infection is still poor. METHODS: Data from the German COVID-19-RMD registry collected between 30 March 2020 and 9 April 2021 were analysed. Ordinal outcome of COVID-19 severity was defined: (1) not hospitalised, (2) hospitalised/not invasively ventilated and (3) invasively ventilated/deceased. Independent associations between demographic and disease features and outcome of COVID-19 were estimated by multivariable ordinal logistic regression using proportional odds model. RESULTS: 2274 patients were included. 83 (3.6%) patients died. Age, male sex, cardiovascular disease, hypertension, chronic lung diseases and chronic kidney disease were independently associated with worse outcome of SARS-CoV-2 infection. Compared with rheumatoid arthritis, patients with psoriatic arthritis showed a better outcome. Disease activity and glucocorticoids were associated with worse outcome. Compared with methotrexate (MTX), TNF inhibitors (TNFi) showed a significant association with better outcome of SARS-CoV-2 infection (OR 0.6, 95% CI0.4 to 0.9). Immunosuppressants (mycophenolate mofetil, azathioprine, cyclophosphamide and ciclosporin) (OR 2.2, 95% CI 1.3 to 3.9), Janus kinase inhibitor (JAKi) (OR 1.8, 95% CI 1.1 to 2.7) and rituximab (OR 5.4, 95% CI 3.3 to 8.8) were independently associated with worse outcome. CONCLUSION: General risk factors for severity of COVID-19 play a similar role in patients with RMDs as in the normal population. Influence of disease activity on COVID-19 outcome is of great importance as patients with high disease activity-even without glucocorticoids-have a worse outcome. Patients on TNFi show a better outcome of SARS-CoV-2 infection than patients on MTX. Immunosuppressants, rituximab and JAKi are associated with more severe course.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Regierer AC, Hasseli R, Schäfer M, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021. PMID: 34670840. doi:10.1136/rmdopen-2021-001896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。